JPRN-jRCT2080220261未知3 期
ong term study of VAH631 in patients with essential hypertension (Extension from B1303 study)
ovartis Pharma K.K.0 个研究点目标入组 350 人开始时间: 2006年6月26日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
入选标准
- •Inclusion criteria
- •- Patients who successfully complete the core study (Protocol 1303)
- •- Outpatients
- •Exclusion criteria
- •- Presence of crucial protocol violation in Protocol 1303
- •- Patients who experienced any adverse events considered serious and drug related in Protocol 1303.
- •Other protocol-defined inclusion/exclusion criteria may apply
排除标准
- 未提供
研究者
相似试验
未知
3 期
Double-blind study of VAH631 in patients with essential hypertension (factorial study)HypertensionJPRN-jRCT2080220234ovartis Pharma K.K.558
招募中
不适用
ifestyle as a Family Eventon-communicable disease (NCD)NL-OMON26277Jeroen Bosch Ziekenhuis10,000
未知
3 期
Double-blind study of VAA489 in patients with essential hypertension (factorial study)HypertensionJPRN-jRCT2080220350ovartis Pharma K.K.1,404
未知
3 期
ong-term study of HP-3060Perennial allergic rhinitisJPRN-jRCT2080222924Hisamitsu Pharmaceutical Co., Inc.
招募中
3 期
Phase III confirmatory study of in patients with venous malformation, lymphatic malformation and Klippel-Trenaunay SyndromeVenous malformation, Lymphatic malformation, Klippel-Trenaunay SyndromeJPRN-jRCT2041230064Hideki Kawabata32